Loading...
Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
Nanoliposomal irinotecan (nal‐IRI) is a liposomal formulation of irinotecan with a longer half‐life (t(1/2)), higher plasma total irinotecan (tIRI), and lower SN‐38 maximum concentration (C (max)) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal‐IRI was performe...
Na minha lista:
| Udgivet i: | Clin Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5697569/ https://ncbi.nlm.nih.gov/pubmed/28445610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.720 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|